Evidence map›Paper›PMID 38214171›Full record

ReviewInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2024

Insights from

Tejaswi Worlikar, Timothy Hall, Man Zhang, Mishal Mendiratta-Lala, Michael Green, Clifford S Cho, Zhen Xu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Histotripsy of Liver Metastases: Short-Term Safety and Imaging Findings.Cardiovascular and interventional radiology · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tejaswi WorlikarDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Timothy HallDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Man ZhangDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Mishal Mendiratta-LalaDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Michael GreenDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Clifford S ChoDepartment of Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Zhen XuDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · USVA Ann Arbor Healthcare System · US

Funding

Novel, Noninvasive, Rapid Tumor Ablation Technology using HistotripsyR01CA211217 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI XU, ZHEN · 2018 to 2022
$2.7M
Transcranial Magnetic Resonance guided Histotripsy (tcMRgHt)R01EB028309 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI XU, ZHEN · 2019 to 2022
$2.4M
Ultrasound-guided Ultra-steerable Histotripsy Array System for Non-invasive treatment of Soft Tissue SarcomaR01EB034399 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Zhen Xu · 2023 to 2026
$2.2M
Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell deathR01CA269394 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI Clifford Cho · 2023 to 2026
$1.8M
NCI NIH HHS R01 CA211217NCI NIH HHS R01 CA269394NIBIB NIH HHS R01 EB028309NIBIB NIH HHS R01 EB034399
6 · The paper itself

Abstract

Histotripsy is the first noninvasive, non-ionizing, and non-thermal ablation technique that mechanically fractionates target tissue into acellular homogenate via controlled acoustic cavitation. Histotripsy has been evaluated for various preclinical applications requiring noninvasive tissue removal including cancer, brain surgery, blood clot and hematoma liquefaction, and correction of neonatal congenital heart defects. Promising preclinical results including local tumor suppression, improved survival outcomes, local and systemic anti-tumor immune responses, and histotripsy-induced abscopal effects have been reported in various animal tumor models. Histotripsy is also being investigated in veterinary patients with spontaneously arising tumors. Research is underway to combine histotripsy with immunotherapy and chemotherapy to improve therapeutic outcomes. In addition to preclinical cancer research, human clinical trials are ongoing for the treatment of liver tumors and renal tumors. Histotripsy has been recently approved by the FDA for noninvasive treatment of liver tumors. This review highlights key learnings from

Indexed as

High-Intensity Focused Ultrasound AblationKidney NeoplasmsLiver NeoplasmsAnimalsHumansInfant, NewbornModels, AnimalResearch Designboiling histotripsycancerHistotripsyimmune effectsin vivopreclinical

Identifiers

PMID38214171
PMCPMC11102041
OpenAlexW4390795192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.